Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 9:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,585 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo:0.9% sodium chloride Clear all
Terminated Early Phase 1 Interventional

Effect of Ketamine on Fatigue Following Cancer Therapy

NCT02317341
View directory record Official record
Conditions
Cancer, Fatigue, Ketamine
Interventions
Ketamine, Placebo (saline), Midazolam, Midazolam(placebo)
Drug
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 15, 2026, 9:50 AM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

The Role of the Opioid System in Placebo Effects on Pain and Social Rejection

NCT04650841
View directory record Official record
Conditions
Pain, Rejection, Placebo Effect
Interventions
Placebo Cream with Naloxone, Control Cream with Naloxone, Placebo Cream with Saline, Control Cream with Saline
Drug
Lead sponsor
Trustees of Dartmouth College
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Hanover, New Hampshire
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 15, 2026, 9:50 AM EDT
Completed Phase 2 Interventional Results available

Thiamine as a Renal Protective Agent in Septic Shock

NCT03550794
View directory record Official record
Conditions
Sepsis, Kidney Injury, Thiamine Deficiency
Interventions
Thiamine Hydrochloride, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Boston, Massachusetts • Manhasset, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 15, 2026, 9:50 AM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers

Adductor Canal Block

NCT04513145
View directory record Official record
Conditions
Osteoarthritis, Total Knee Replacement
Interventions
Ropivacaine injection, Saline Injection, Total Knee Arthroplasty
Drug · Procedure
Lead sponsor
OrthoCarolina Research Institute, Inc.
Other
Eligibility
30 Years to 85 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 15, 2026, 9:50 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effects of Sedatives on Tobacco Use Disorder Version 2

NCT05505630
View directory record Official record
Conditions
Tobacco Smoking
Interventions
Ketamine, Midazolam, Dexmedetomidine, Saline
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 15, 2026, 9:50 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Sphenopalatine Ganglion Block and Cold Induced Headaches

NCT06310200
View directory record Official record
Conditions
Cold Induced Headache, Brain Freeze, Cold Induced Cephalgia, Headache
Interventions
Lidocaine Topical 4% Topical Solution, Bitrex, normal saline
Drug
Lead sponsor
Wright State University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 15, 2026, 9:50 AM EDT
Completed Phase 2 Interventional Results available

N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients

NCT00780962
View directory record Official record
Conditions
Radiocontrast Nephropathy
Interventions
N-Acetylcysteine (NAC), 0.9% Sodium-chloride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 15, 2026, 9:50 AM EDT
Completed Phase 2 Interventional Results available

The Effect of Nebulized Albuterol on Donor Oxygenation

NCT00310401
View directory record Official record
Conditions
Brain Death, Organ Donor, Pulmonary Edema
Interventions
Albuterol, Saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
14 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2018 · Synced Oct 15, 2026, 9:50 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection

NCT01887912
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
C. difficile Toxoid Vaccine, Placebo: 0.9% normal saline
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
50 Years and older
Enrollment
9,302 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
142
States / cities
Huntsville, Alabama • Mobile, Alabama • Flagstaff, Arizona + 124 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 15, 2026, 9:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PHASE 1 SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19

NCT04784767
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant), Sodium chloride, USP, for injection (0.9% NaCl), 50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)
Biological · Drug
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Oct 15, 2026, 9:50 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study Assessing KB304 for the Treatment of Wrinkles in Women

NCT06724900
View directory record Official record
Conditions
Wrinkles in Decolletage, Pigmentation, Décolleté Wrinkles
Interventions
KB304, 0.9% Normal Saline (NS)
Biological · Drug
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 15, 2026, 9:50 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Efficacy of FMT in Individuals With One or More Recurrences of Clostridium Difficile Associated Disease (CDAD)

NCT03548051
View directory record Official record
Conditions
Clostridial Infection, Dysbiosis, Probiotic Therapy
Interventions
Fecal Microbiota Transplantation (FMT), Saline
Procedure · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Decatur, Georgia • Durham, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 15, 2026, 9:50 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age

NCT03313037
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Multivalent, Prevnar 13, PPSV23, Saline
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
60 Years to 64 Years
Enrollment
444 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
14
States / cities
Anaheim, California • Coral Gables, Florida • DeLand, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 15, 2026, 9:50 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.

NCT05045144
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3(120 μg), Flu Quadrivalent influenza vaccine (15 μg HA), Placebo
Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
1,586 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
5
States / cities
West Palm Beach, Florida • Stockbridge, Georgia • Peoria, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 15, 2026, 9:50 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant

NCT04368988
View directory record Official record
Conditions
COVID-19
Interventions
SARS-CoV-2 rS - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1, Normal saline solution (NSS), Placebo - Phase 1, Normal saline solution (NSS), Placebo - Phase 2, SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1, Normal saline solution (NSS), Placebo, Day 21 - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 84 Years
Enrollment
1,419 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
8
States / cities
Savannah, Georgia • Meridian, Idaho • Newton, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 15, 2026, 9:50 AM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults

NCT05258669
View directory record Official record
Conditions
COVID-19
Interventions
BBV152
Biological
Lead sponsor
Ocugen
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
10
States / cities
Tempe, Arizona • Miami, Florida • Miami Lakes, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 15, 2026, 9:50 AM EDT
Withdrawn Phase 2 Interventional

Efficacy of Acetaminophen in Posterior Fossa Surgery

NCT02532322
View directory record Official record
Conditions
Arnold-Chiari Malformation, Posterior Fossa Tumors
Interventions
IV acetaminophen, normal saline
Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
2 Years to 12 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 15, 2026, 9:50 AM EDT
Completed Phase 1 Interventional

Pilot Study of Bumetanide for Newborn Seizures

NCT00830531
View directory record Official record
Conditions
Seizures
Interventions
Bumetanide, Normal Saline as Placebo
Drug
Lead sponsor
Soul, Janet , M.D.
Individual
Eligibility
Up to 44 Weeks
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 15, 2026, 9:50 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Intrauterine Device Insertion Pain Management

NCT06951191
View directory record Official record
Conditions
IUD Insertion Pain, IUD Insertion
Interventions
Benzocaine 20%, Lidocaine 2%, Sham injection, Saline 0.9%
Drug · Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 15, 2026, 9:50 AM EDT
Terminated Phase 4 Interventional Results available

Aerosolized Antibiotics in the Treatment of Ventilator Associated Pneumonia

NCT02478710
View directory record Official record
Conditions
Pneumonia, Ventilator-Associated
Interventions
Aerosolized Tobramycin or Vancomycin, Aerosolized Placebo
Drug
Lead sponsor
Wright State University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 15, 2026, 9:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria

NCT03392896
View directory record Official record
Conditions
Primary Hyperoxaluria
Interventions
DCR-PHXC, Placebo
Drug
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
6 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 15, 2026, 9:50 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)

NCT02836496
View directory record Official record
Conditions
Hypereosinophilic Syndrome
Interventions
Mepolizumab 300 mg, Placebo matching mepolizumab, Active OCS capsules (5 mg prednisolone or prednisone), Placebo matching OCS capsules
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
San Diego, California • New Haven, Connecticut • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Oct 15, 2026, 9:50 AM EDT
Completed Not applicable Interventional Results available

Using Ultrasound to Predict Response to Intraarticular Corticosteroids in Knee Osteoarthritis

NCT00746889
View directory record Official record
Conditions
Osteoarthritis
Interventions
triamcinolone acetonide, saline
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2010 · Synced Oct 15, 2026, 9:50 AM EDT
Active, not recruiting Phase 3 Interventional

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

NCT07018713
View directory record Official record
Conditions
Chronic Migraine
Interventions
Xeomin, Placebo
Drug
Lead sponsor
Merz Therapeutics GmbH
Industry
Eligibility
18 Years and older
Enrollment
808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
48
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 15, 2026, 9:50 AM EDT